TNGX News and Press, Tango Therapeutics Inc. From 06/27/22

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics , Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the company was added to the Russell 2000 ® , Ru...

CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participat...

Tango Therapeutics press release (NASDAQ:TNGX): Q1 GAAP EPS of -$0.29 misses by $0.01. Revenue of $5.76M (-9.9% Y/Y) misses by $0.07M. For further details see: Tango Therapeutics GAAP EPS of -$0.29 misses by $0.01, revenue of $5.76M misses by $0.07M

– Phase 1/2 trial of TNG908, a synthetic lethal PRMT5 inhibitor, for the treatment of MTAP-deleted solid tumors open for enrollment – – Declared TNG462 as a development candidate - a next-generation PRMT5 inhibitor for MTAP-deleted solid tumors – ...

CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics , Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participat...

Tango Therapeutics press release (NASDAQ:TNGX): Q4 GAAP EPS of -$0.25 in-line. Revenue of $5.72M (-37.4% Y/Y) misses by $1.01M. For further details see: Tango Therapeutics GAAP EPS of -$0.25 in-line, revenue of $5.72M misses by $1.01M

- TNG908 receives Fast Track designation, expects Phase 1/2 trial to start in 2Q 2022 - - Pipeline programs progressing throughout 2022 - - Strong cash position of $485 million expected to support operations into second half of 2024 - CAMBRIDGE, Mass., March 28...

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that three abstracts have been selected for presentation as poster...

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the presentation of an e-Poster at the 2022 European Society for M...

The following slide deck was published by Tango Therapeutics, Inc. in conjunction with this event. For further details see: Tango Therapeutics (TNGX) Investor Presentation - Slideshow